REYKJAVIK, Iceland, July 6, 2012 /CNW/ - A recent clinical study on an
Icelandic natural product has shown it to be effective against
"nocturia" in those with low or diminished bladder capacity. Nocturia
is the medical definition of the frequent need to urinate at night.
This problem is common among men with prostate enlargement as well as
people of all ages with an overactive bladder.
(Logo: http://photos.prnewswire.com/prnh/20120706/543346-a )
(Photo: http://photos.prnewswire.com/prnh/20120706/543346-b )
(Photo: http://photos.prnewswire.com/prnh/20120706/543346-c )
The product, SagaPro, which is made from the herb "Angelica
archangelica", has been produced by SagaMedica in Iceland since 2005
and is very popular among nocturia sufferers. SagaPro has now been
clinically studied and a peer-reviewed paper on the study will be
published in the Scandinavian Journal of Urology and Nephrology.
Increased nocturnal bladder volume
The study was performed in Iceland by Encode Ltd. and the whole process
lasted one year. A total of sixty-nine participants, all of them men
with "lower urinary tract symptoms", which includes prostate
enlargement, were required to keep a detailed record of their nocturnal
restroom trips as well as the volume of urine before and after a period
of 8 weeks while they took either SagaPro or a placebo.
Findings showed significant results among different subgroups. In that
regard, SagaPro had a pronounced effect on bladder volume and urinary
frequency, two factors which affect the duration and quality of sleep.
"The findings were interesting in many ways. For instance, we saw that
SagaPro had a significant and positive effect on those who had a low or
diminished nocturnal bladder capacity. This knowledge will help us
design other studies on SagaPro in the future" says Dr. Steinthor
Sigurdsson, Ph.D. and a researcher at SagaMedica.
Not just a prostate product
The study sheds a light on how SagaPro can help those with prostate
enlargement which affects a majority of men over 60. As SagaPro affects
the bladder it indirectly helps men with prostate enlargement whose
main complaint tends to be increased urinary frequency. The presence of
a bladder-relaxing flavonoid in SagaPro had previously suggested the
product worked through a bladder-related mechanism. Successful use by
women and young people with enuresis (bed-wetting) also hinted at this
and now the clinical study confirms that SagaPro affects the bladder,
thereby helping sufferers of frequent urination.
Helps international marketing
SagaPro is currently marketed in over 200 retail outlets in the US and
Canada. Perla Bjork Egilsdottir is SagaMedica's marketing manager: "The
positive outcome of the clinical study will no doubt help us in further
marketing SagaPro internationally. We expect the results to greatly
increase our sales since the brand "SagaPro" has now been clinically
verified for both safety and efficacy; not just the product's
individual ingredients," she says.
The clinical study on SagaPro is preceded by SagaMedica's considerable
research on the Angelica herb. This is the 6th peer-reviewed paper the
company's research team publishes since it was founded in 2000. The
paper is entitled: "A parallel, randomised, double blind, placebo
controlled study to investigate the effect of SagaPro on nocturia in
men". Authors are the MD's Gudmundur Geirsson and Hrefna Gudmundsdottir
and the biochemists Steinthor Sigurdsson, Perla B. Egilsdottir and
professor Sigmundur Gudbjarnason.
Previous studies published by the company research team looked at the
herb's potential benefits ranging from effects on a neurotransmitter to
promote memory health to the potential uses of Angelica in the battle
against cancer. Clinical studies on those properties are expected to
follow in the future.
More information about SagaPro can be found on the company's website: http://www.sagamedica.com
1. DOI NUMBER - 10.3109/00365599.2012.695390 [in press]
For further information:
Perla Björk Egilsdóttir, Director of Marketing, Phone: +354-899-4422, Email:firstname.lastname@example.org